Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
Anlon Healthcare IPO is a book build issue of ₹121.03 crores. The issue is entirely a fresh issue of 1.33 crore shares of ₹121.03 crore.
Anlon Healthcare IPO bidding started from Aug 26, 2025 and ended on Aug 29, 2025. The allotment for Anlon Healthcare IPO was finalized on Sep 1, 2025. Anlon Healthcare IPO will list on BSE, NSE with a tentative listing date fixed as Sep 3, 2025.
Anlon Healthcare IPO price band is set at ₹91.00 per share . The lot size for an application is 164. The minimum amount of investment required by an retail is ₹14,924 (164 shares) (based on upper price). The lot size investment for sNII is 14 lots (2,296 shares), amounting to ₹2,08,936, and for bNII, it is 68 lots (11,152 shares), amounting to ₹10,14,832.
Interactive Financial Services Ltd. is the book running lead manager and Kfin Technologies Ltd. is the registrar of the issue.
Refer to Anlon Healthcare IPO RHP for detailed Information.
| IPO Date | August 26, 2025 to August 29, 2025 |
| Listing Date | September 3, 2025 |
| Face Value | ₹10 per share |
| Issue Price Band | ₹86 to ₹91 per share |
| Issue Price Final | ₹91 per share |
| Lot Size | 164 Shares |
| Sale Type | Fresh Capital |
| Total Issue Size | 1,33,00,000 shares (aggregating up to ₹121.03 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Share Holding Pre Issue | 3,98,51,500 shares |
| Share Holding Post Issue | 5,31,51,500 shares |
Anlon Healthcare IPO offers total 1,33,00,000 shares. Out of which 99,75,000 (75.00%) allocated to QIB, 19,95,000 (15.00%) allocated to NII, 13,30,000 (10.00%) allocated to RII.
| Investor Category | Shares Offered | Maximum Allottees |
|---|---|---|
| QIB Shares Offered | 99,75,000 (75.00%) | NA |
| NII (HNI) Shares Offered | 19,95,000 (15.00%) | NA |
| − bNII > ₹10L | 13,30,000 (10.00%) | 579 |
| − sNII < ₹10L | 6,65,000 (5.00%) | 289 |
| Retail Shares Offered | 13,30,000 (10.00%) | 8,109 |
| Total Shares Offered | 1,33,00,000 (100.00%) |
Anlon Healthcare IPO opens on August 26, 2025, and closes on August 29, 2025.
| IPO Open Date | Tue, Aug 26, 2025 |
| IPO Close Date | Fri, Aug 29, 2025 |
| Tentative Allotment | Mon, Sep 1, 2025 |
| Initiation of Refunds | Tue, Sep 2, 2025 |
| Credit of Shares to Demat | Tue, Sep 2, 2025 |
| Tentative Listing Date | Wed, Sep 3, 2025 |
| Cut-off time for UPI mandate confirmation | 5 PM on Fri, Aug 29, 2025 |
Investors can bid for a minimum of 164 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Individual Investors (Retail) and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 164 | ₹14,924 |
| Retail (Max) | 13 | 2,132 | ₹1,94,012 |
| S-HNI (Min) | 14 | 2,296 | ₹2,08,936 |
| S-HNI (Max) | 67 | 10,988 | ₹9,99,908 |
| B-HNI (Min) | 68 | 11,152 | ₹10,14,832 |
Note : The value will be calculated using Equity Dilution = Share Holding Pre Issue - Share Holding Post Issue
Incorporated in 2013, Anlon Healthcare Limited is a chemical manufacturing company engaged in manufacturing of Pharma Intermediates and active pharmaceutical ingredients (APIs).
The company manufactures high-purity pharmaceutical intermediates (for API production) and active pharmaceutical ingredients (used in formulations for medicines, nutraceuticals, personal care, and animal health products).
The company offers pharmaceutical intermediates, APIs for medicines, nutraceuticals, personal care, and veterinary products, all manufactured following Indian and international pharmacopeia standards like IP, BP, EP, JP, and USP.
In addition to manufacturing Pharma Intermediates and APIs to global standards, the company now offers custom manufacturing for complex chemicals, exceeding purity standards and reducing impurities to meet specific customer needs.
The company has received Drug Master File (DMF) approval from ANVISA, NMPA, and PMDA for loxoprofen sodium dihydrate and loxoprofen acid APIs. The company has filed 21 DMFs with global authorities and is in the process of filing for Ketoprofen and Dexketoprofen Trometamol approvals.
The company ensures product quality through rigorous testing, analysis, and process improvements. Supported by four labs, the 34-member team, including 24 science graduates, ensures products meet customer and industry standards.
The company's product portfolio consists of sixty-five (65) commercialised products and twenty-eight (28) products at pilot stage and forty-nine (49) products at laboratory testing stage/ laboratory scale stage.
Products:
Competitive Strengths:
Anlon Healthcare Ltd.'s revenue increased by 81% and profit after tax (PAT) rose by 112% between the financial year ending with March 31, 2025 and March 31, 2024.
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
| Assets | 181.30 | 128.00 | 111.55 |
| Total Income | 120.46 | 66.69 | 113.12 |
| Profit After Tax | 20.52 | 9.66 | 5.82 |
| EBITDA | 32.38 | 15.57 | 12.66 |
| Net Worth | 80.42 | 21.03 | 7.37 |
| Reserves and Surplus | 40.57 | 5.03 | -4.63 |
| Total Borrowing | 58.35 | 74.56 | 66.39 |
| Amount in ₹ Crore | |||
The market capitalization of Anlon Healthcare IPO is ₹483.68 Cr.
KPI as of Mon, Mar 31, 2025.
| KPI | Values |
|---|---|
| ROE | 40.45% |
| ROCE | 21.93% |
| Debt/Equity | 0.73 |
| RoNW | 25.51% |
| PAT Margin | 17.06% |
| EBITDA Margin | 26.88% |
| Price to Book Value | 4.51 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS Rs | 5.15 | 3.86 |
| P/E (x) | 17.67 | 23.57 |
The Company Anlon Healthcare IPO proposes to utilise the Net Proceeds from the Issue towards the following objects:
| S.No. | Objects of the Issue | Expected Amount (₹ in crores) |
|---|---|---|
| 1 | Funding capital expenditure requirements for Proposed Expansion | 30.72 |
| 2 | Full or part repayment and/or prepayment of certain outstanding secured borrowingssecured borrowing (term loan)availed by the Company | 5.00 |
| 3 | Funding the working capital requirements of the Company | 43.15 |
| 4 | General corporate purposes | 270.30 |
[Dilip Davda] AHL is engaged in the manufacture and marketing of specialized APIs as per global standards. It claims to be the first one to manufacture Loxoprofen and related products. The company marked set back in its top line for FY24 following its registration process with Brazil. Based on its recent financial data, the IPO appears aggressively priced. Only well-informed/cash surplus investors may park moderate funds for long term. Read detail review...
| Listing Date | September 3, 2025 |
| BSE Script Code | 544497 |
| NSE Symbol | AHCL |
| ISIN | INE0Y8W01017 |
| Final Issue Price | ₹91 per share |
| NSE Listing Group | BE |
| BSE Listing Group | B |
Anlon Healthcare Ltd.
101/102, Silvercoin Complex,
Opp.Crystal Mall,
Kalawad Road,
Rajkot, Gujarat, 360005
Phone: +91 281 2562538
Email: cs@anloncro.com
Website: http://www.anlon.in/
Kfin Technologies Ltd.
Phone: 04067162222, 04079611000
Email: ahl.ipo@kfintech.com
Website: https://ipostatus.kfintech.com/
Anlon Healthcare IPO is a main-board IPO of 1,33,00,000 equity shares of the face value of ₹10 aggregating up to ₹121.03 Crores. The issue is priced at ₹91 per share. The minimum order quantity is 164.
The IPO opens on August 26, 2025, and closes on August 29, 2025.
Kfin Technologies Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Anlon Healthcare IPO using UPI as a payment gateway. Zerodha customers can apply in Anlon Healthcare IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Anlon Healthcare IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Anlon Healthcare IPO opens on August 26, 2025 and closes on August 29, 2025.
Anlon Healthcare IPO lot size is 164, and the minimum amount required for application is ₹14,924.
You can apply in Anlon Healthcare IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Anlon Healthcare IPO will be done on Monday, September 1, 2025, and the allotted shares will be credited to your demat account by Tuesday, September 2, 2025. Check the Anlon Healthcare IPO allotment status.
The Anlon Healthcare IPO listing date is on Wednesday, September 3, 2025.
Useful Articles
RHP